IS
ISPC.US iSpecimen Inc
- Market cap
- USD 1.66M
- P/E
- -
- P/B
- 0.96x
- ROE
- -419.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ISPC.US undervalued?
Graham numberThe Graham number of iSpecimen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
iSpecimen Inc fundamental analysis
No fundamental analysis for iSpecimen Inc yet.
iSpecimen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About iSpecimen Inc
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including bio…
Full company profileiSpecimen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
iSpecimen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 4.39M | 4.30M | 8.18M | 11.1M | 10.4M | 9.93M | 9.29M | 1.93M | 616K |
| Gross Profit | 2.03M | 2.17M | 4.60M | 5.89M | 5.65M | 5.11M | 3.99M | 24.1K | -122K |
| Operating Income | -3.36M | -3.88M | -2.41M | -5.93M | -10.2M | -11.2M | -12.7M | -8.98M | -7.80M |
| EBITDA | -3.79M | -2.52M | -1.74M | -5.86M | -8.80M | -8.75M | -10.4M | -8.75M | -6.60M |
| Net Income | -5.35M | -4.73M | -4.65M | -8.96M | -10.2M | -11.1M | -12.5M | -10.5M | -7.28M |
| EPS | -652 | -576 | -567 | -821 | -927 | -982 | -703 | -91 | -5.22 |
| Balance Sheet | |||||||||
| Total Assets | 4.04M | 4.21M | 6.21M | 35.7M | 24.6M | 15.8M | 9.35M | 9.53M | 7.39M |
| Total Liabilities | 22.5M | 26.9M | 33.5M | 5.93M | 4.31M | 6.08M | 6.04M | 6.44M | 5.66M |
| Shareholders' Equity | -18.4M | -22.7M | -27.3M | 29.8M | 20.3M | 9.74M | 3.31M | 3.09M | 1.74M |
| Cash & Short-term Investments | 1.13M | 53.9K | 696K | 27.7M | 15.3M | 5.01M | 1.88M | 6.88M | 4.41M |
| Total Debt | 6.97M | 10.6M | 12.8M | 3.42M | 186K | 196K | 312K | 269K | 241K |
| Cash Flow | |||||||||
| Operating Cash Flow | -2.68M | -2.68M | -288K | -10.7M | -5.82M | -5.81M | -8.26M | -4.24M | -8.10M |
| Capital Expenditure | 1.03M | 1.48M | 1.10M | 1.04M | 3.19M | 4.74M | 56.5K | 454.00 | 18.00 |
| Free Cash Flow | -3.71M | -4.16M | -1.39M | -11.7M | -9.01M | -10.6M | -8.32M | -4.24M | -8.10M |
| Ratios | |||||||||
| ROE | - | - | - | -30.1% | -50.4% | -113.9% | -377.5% | -339.6% | -419.0% |
| ROA | -132.2% | -112.2% | -74.9% | -25.1% | -41.6% | -70.2% | -133.7% | -110.0% | -98.4% |
| Net Profit Margin | -121.7% | -110.0% | -56.8% | -80.5% | -98.5% | -111.8% | -134.5% | -543.7% | -1,181.4% |
| Debt to Equity | - | - | - | 0.11x | 0.01x | 0.02x | 0.09x | 0.09x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
iSpecimen Inc dividends
iSpecimen Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:40 on Apr 28, 2026.
Who owns iSpecimen Inc
- Insiders 0.15%
- Institutions 0.58%
- Public & others 99.27%
- Shares outstanding 2.52M
- Free float 2.52M
Top funds holding ISPC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 12.4K | 0.49% | 0.00% | Sep 2026 |
Top institutions holding ISPC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| UBS Group AG | 32.0K | 1.27% | +2,283.71% | Jun 2026 |
| Jane Street Group LLC | 24.4K | 0.97% | +1,655.14% | Jun 2026 |
| IFP Advisors, LLC | 8.20K | 0.33% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 219.00 | 0.01% | +31.93% | Jun 2026 |
| BlackRock Inc | 71.00 | 0.00% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 31.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Sachetta LLC | 0.00 | 0.00% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
iSpecimen Inc company profile
- Company name
- iSpecimen Inc
- Ticker
- ISPC.US
- Exchange
- USA Stocks
- Listed since
- Jun 17, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 8 Cabot Road, Woburn, MA, United States, 01801
- Phone
- 781 301 6700
- Website
- ispecimen.com
About iSpecimen Inc
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
iSpecimen Inc management
2- Mr. Yuying LiangChief Financial Officer · born 1990
- Mr. Shahin BehroyanChief Executive Officer · born 1987